Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCL6 | P41182 | 1/20 | 0.44 |
| ▸ | NUDT1 | P36639 | 2/20 | 0.38 |
| ▸ | SYK | P43405 | 2/20 | 0.32 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.31 |
| ▸ | P2RX2 | Q9UBL9 | 1/20 | 0.31 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.31 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.31 |
| ▸ | SRC | P12931 | 1/20 | 0.31 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.31 |
| ▸ | FEN1 | P39748 | 4/20 | 0.30 |
| ▸ | ALOX5AP | P20292 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL179356 | 0.88 | BCL6 (0.46) | BCL6NUDT1SYKP2RX3P2RX2 | |
| SCHEMBL179464 | 0.88 | BCL6 (0.46) | BCL6NUDT1SYKP2RX3P2RX2 | |
| SCHEMBL179505 | 0.88 | BCL6 (0.46) | BCL6NUDT1SYKP2RX3P2RX2 | |
| SCHEMBL2745520 | 0.80 | BCL6 (0.51) | BCL6NUDT1SYKP2RX3P2RX2 | |
| SCHEMBL18855175 | 0.78 | BCL6 (0.49) | BCL6NUDT1SYKP2RX3P2RX2 | |
| SCHEMBL18879368 | 0.78 | BCL6 (0.49) | BCL6NUDT1SYKP2RX3P2RX2 | |
| SCHEMBL9925932 | 0.75 | BCL6 (0.46) | BCL6NUDT1SYK | |
| SCHEMBL9925942 | 0.75 | BCL6 (0.46) | BCL6NUDT1SYK | |
| SCHEMBL218364 | 0.75 | BCL6 (0.46) | BCL6NUDT1SYK | |
| SCHEMBL179460 | 0.75 | BCL6 (0.43) | BCL6NUDT1SYKFEN1ALOX5AP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210060022-A1 | TREATMENT OF CANCERS USING PI3 KINASE ISOFORM MODULATORS | INFINITY PHARMACEUTICALS, INC. | 2021-03-04 | — | — | US | disclosed |
| US-20180098983-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | INTELLIKINE, INC. | 2018-04-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180098983-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | PIK3CA, AKT3, PIK3C2A | BCL6 3204/4885NUDT1 1283/4885SYK 475/4885 |
| US-20210060022-A1 | TREATMENT OF CANCERS USING PI3 KINASE ISOFORM MODULATORS | PIK3CA, MCL1, PIK3CB | BCL6 438/4885NUDT1 1970/4885SYK 784/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.